- $24.59bn
- $21.44bn
- $8.26m
Roivant Sciences Ltd reports results for the quarter ended December 31 - Earnings Summary
Brief: Roivant Sciences Q3 EPS USD 0.23
U.S. STOCKS ON THE MOVE-PSQ Holdings, Core Scientific, Keros
U.S. STOCKS ON THE MOVE-BlackRock, Terns Pharma, PSQ Holdings
U.S. STOCKS ON THE MOVE-Citi Trends, PG&E, BlackRock
Roivant falls as lung disease drug fails in mid-stage study
Roivant's lung disease drug fails mid-stage trial (updated)
Roivant's lung disease drug fails mid-stage trial
Musk, Ramaswamy will lean on Supreme Court rulings to cut federal agencies (updated)
Musk, Ramaswamy plan to lean on Supreme Court rulings to reduce federal agencies reach
Explainer: How Musk's US government efficiency panel might work
Explainer: How Musk's US government efficiency panel might work
Roivant Sciences Ltd reports results for the quarter ended September 30 - Earnings Summary
Brief: Roivant Sciences Q2 Operating Expenses USD 346.188 Million
U.S. STOCKS ON THE MOVE-United States Steel, Ambac Financial, Apple
U.S. STOCKS ON THE MOVE-Powerfleet, NMI, Vivos Therapeutics
Brief: Organon To Acquire Dermavant Including Its Innovative Dermatologic Therapy, Vtama® (Tapinarof) Cream, 1%
Roivant rises as Organon agrees to buy its unit for up to $1.2 billion
Organon to buy skin therapy developer Dermavant for up to $1.2 billion (updated)